Navigation Links
Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
Date:4/25/2008

Ohm Laboratories to Market in OTC Private Label Market

PRINCETON, N.J., April 25 /PRNewswire/ -- Ohm Laboratories Inc (Ohm), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1 mg/mL (OTC). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ohm formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Children's Zyrtec Oral Solution (Allergy) and Children's Zyrtec Oral Solution (Hives-Relief), 1mg/mL of McNeil Consumer Healthcare. Total annual market sales for Cetirizine Hydrochloride Syrup as a prescription only product were $157 million (IMS - MAT: December 2007).

Cetirizine Hydrochloride is indicated for the temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Other indications include relief from itching due to hives (urticaria).

"We are pleased to receive this final approval for Cetirizine Hydrochloride Oral Solution that has proven its clinical value and utility in both adults and children. We are pleased to offer this preferred formulation that will meet the needs of all patients who need this medication in response to allergic reactions as an over-the-counter product. This product formulation further expands our portfolio of affordable generic alternatives and will be launched immediately to all classes of trade participating in the OTC private label market," said Jim Meehan, Vice President of Sales and Distribution for Ohm Laboratories, a wholly owned subsidiary company of RLL.

Ohm, based in North Brunswick, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Ind
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
3. Ranbaxy Receives Tentative Approval For Valsartan Tablets
4. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
5. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Michael E. DeBakey Receives Congressional Gold Medal
8. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
9. Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards
10. The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA)
11. PainCare Receives Notices From American Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... DC (PRWEB) September 15, 2014 ... payment initiatives that bring providers on board as ... member satisfaction. When bundled payment programs are designed ... financial incentives, incentivize hospitals to work collaboratively with ... procedure-specific tally. On Sept. 24, the Atlantic Information ...
(Date:9/15/2014)... More than 30 million additional Americans ... Care Act. This fact begs the question “are there ... reform and an aging population create a demand for ... are trying to stay on top of the anticipated ... 204 days to fill, according to the Association of ...
(Date:9/15/2014)... FL (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... what’s not; what the startup business requirements are in ... the new business. , Speakers include industry professionals, such ... Health Center in Oakland,CA and cannabis business consultant ... , who are already successfully running legal marijuana businesses ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... (PRWEB) September 14, 2014 Government ... growth of the patient handling equipment market , ... lucrative growth potential for the next five years. ... the rise in geriatric population and increasing lifestyle ... leading to increased disabilities. Further the market is ...
Breaking Medicine News(10 mins):Health News:Sept. 24 Webinar to Profile Geisinger Health System, BCBS of North Carolina’s Successful Bundled-Payment Programs 2Health News:Affordable Care Act Poses Challenge for Hospital Recruiters, with Nationwide Physician Shortage Looming in the Near Future 2Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4
... 57 million Americans currently living with "pre-diabetes" could benefit from ... a new study published in this month,s American Journal ... Weight Watchers group program, overweight or obese adults who attended ... lost weight, but also significantly reduced fasting glucose and insulin ...
... Georgia Institute of Technology has received a $100,000 Grand ... Foundation. The grant will support an innovative global health ... in Georgia Tech,s School of Mechanical Engineering, titled "Complement-based ... grants announced by the Gates Foundation in the fourth ...
... successful testing of a sensor that can instantly tell whether ... by emergency room doctors to determine whether a patient has ... diabetics do not take enough insulin. Someday the technology may ... determine whether they need more insulin. A report on the ...
... Through ... and rare diseases are possible before they ever manifest. The future of medicine starts ... (PRWEB) ... world’s first predictive medicine company, is working with healthcare providers to PREDICT, PREVENT, and ...
... ... ... -- IT-Lifeline, the Northwest’s foremost provider of disaster recovery and business continuity solutions, and ... have entered into a joint marketing agreement to provide a suite of Disaster Recovery ...
... fingerroot inhibited production of carcinogenic compounds , THURSDAY, May ... to your burgers before tossing them on the grill ... of the meat, but they can also cut the ... beef. , Scientists at Kansas State University (KSU) found ...
Cached Medicine News:Health News:New study finds attending Weight Watchers meetings helps reduce the risk for type 2 diabetes 2Health News:Georgia Tech awarded Gates Foundation grant for innovative global health research 2Health News:Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease 2Health News:Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease 3Health News:IT-Lifeline, Inc and OptiStor Technologies, Inc. Enter Joint Marketing Agreement 2Health News:IT-Lifeline, Inc and OptiStor Technologies, Inc. Enter Joint Marketing Agreement 3Health News:Some Spices Cut Cancer Risk That Comes With Grilled Burgers 2
(Date:9/14/2014)... 2014  Abbott announced today positive one-year clinical ... randomized, controlled trial comparing the safety and effectiveness ... market-leading metallic XIENCE family of DES.  The trial, ... included 501 people with coronary artery disease (CAD), ... results were featured at a late-breaking session at ...
(Date:9/12/2014)... Colorado eye care provider Vision Care Specialists announced expansion ... high quality eye care services. Photo - http://photos.prnewswire.com/prnh/20140912/145684 ... locations in Aurora , Lakewood ... days a week. Hours are Monday, Tuesday, Thursday and Friday 7:45 ... Saturday 7:45 AM to 2:30 PM. The downtown Denver ...
(Date:9/12/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... U.S. Food and Drug Administration (FDA) has granted ... monoclonal antibody (mAb) combination for the treatment of ... the U.S., Orphan Drug Designation provides a variety ...
Breaking Medicine Technology:ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 2ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 3ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 4ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 5Colorado Eye Care: Vision Care Specialists Expands Hours, adds Optometrists to Denver Locations 2Colorado Eye Care: Vision Care Specialists Expands Hours, adds Optometrists to Denver Locations 3Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 2Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 3
... and Efficacy Data Reported ... Enrollment Advancing Ahead of Schedule, SOUTH SAN FRANCISCO, ... ) today presented an update of interim,data from the ... product,candidate, voreloxin (formerly SNS-595), in platinum-resistant ovarian,cancer patients at ...
... Results Confirm Previously Demonstrated Survival Advantages of Tarceva in ... This Difficult-to-Treat Disease ... - ABSTRACT No: 4507, ... Tarceva (erlotinib) and chemotherapy significantly,improves the time patients with metastatic pancreatic cancer ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 2Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: